Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a new bevacizumab drug made by Mabscale, LLC, compared to Avastin, both combined with paclitaxel and carboplatin, for treating adults with advanced or inoperable non-squamous non-small cell lung cancer NSCLC. This phase III trial aims to show that the new bevacizumab works as well and is as safe as Avastin. The study also looks at how the drug is processed in the body. Participants are randomly assigned to one of two groups. One group receives the Mabscale bevacizumab with paclitaxel and carboplatin, and the other gets Avastin with the same chemotherapy drugs. Treatment cycles last about three weeks, with up to six cycles initially. After that, eligible patients continue with bevacizumab alone every three weeks. The study is double-blind, so neither patients nor researchers know who receives which bevacizumab. During the study, patients will undergo regular assessments including tumor measurements and blood tests. Researchers measure the tumor response at 18 weeks and track progression-free and overall survival at 18 and 42 weeks. The duration of response is also evaluated up to 48 weeks. Safety and side effects are closely monitored throughout the trial, which started in 2023 and will continue until 2027. Participants are followed closely to assess the treatments impact and safety.
Actively Recruiting
Researchers are conducting a multicenter observational study in the Russian Federation focusing on patients with aggressive high-volume metastatic hormone-sensitive prostate cancer mHSPC. The study aims to analyze treatment patterns and evaluate homologous recombination repair mutations HRRm using circulating tumor DNA ctDNA. The population includes those with high-aggressive Gleason score 8-10 and high-volume disease, with known tumor HRRm status determined from routine tumor samples. Approximately 230 patients will be enrolled, equally representing HRRm and wild-type HRR HRRwt groups. This study involves no additional procedures beyond routine clinical practice. Data collection includes two visits the baseline visit gathers demographic, clinical, and treatment history from medical records and patient interviews, as well as blood samples for ctDNA and HRRm testing performed centrally. The final visit occurs at disease progression or after about 12 months to collect follow-up data on progression to metastatic castration-resistant prostate cancer mCRPC and further treatments. Follow-up data may be collected by telephone if the patient cannot visit the study site. Participants contribute data through medical record reviews, interviews, and routine blood sampling. Researchers will monitor various outcomes including treatment types and durations, progression timelines, mutation presence in ctDNA, and clinical characteristics like Gleason scores and metastasis sites. Data will be entered into electronic records, with the study lasting about 36 months until enrollment and follow-up are complete.
Actively Recruiting
Researchers are conducting a national, multicenter, prospective observational study focusing on molecular profiling and first-line treatment approaches for patients with aggressive advanced endometrial cancer stage III-IV in the Russian Federation. The study aims to collect real-world data on the prevalence of specific molecular markers such as POLE mutations, mismatch repair status, p53 abnormalities, HER2, and PD-L1 expression, alongside demographic and clinical characteristics of these patients. The study will include approximately 500 female patients newly diagnosed with aggressive advanced endometrial cancer subtypes who have available biopsy or postoperative archival tumor samples. No additional procedures beyond routine clinical practice will be performed. Molecular testing will be conducted centrally using immunohistochemistry and genetic sequencing techniques on tumor samples. Data collection will occur during two visits the baseline visit to gather demographic, clinical, and treatment information, and a follow-up visit six months later or at disease progression to collect further treatment and progression data. Participants will have their clinical and molecular data entered into electronic records by study physicians. The study will monitor several primary outcomes related to the rates of molecular marker positivity over 24 months and secondary outcomes including chemotherapy use, disease progression, patient demographics, and tumor characteristics over 33 months. The total study duration is expected to be about 27 months or until 500 eligible patients have been enrolled and their data collected, including follow-up.
Actively Recruiting
Researchers are conducting a large observational study involving 5,000 adult patients across about 50 regions in Russia who have uncontrolled severe asthma and are receiving standard treatments except biologic therapies. The study aims to better understand the characteristics, treatment patterns, and clinical outcomes of these patients, as there is currently limited data on this population in Russia. The study will not interfere with routine clinical care and is designed to collect comprehensive real-world information. Participants will have one study visit to gather demographic and clinical data without any additional diagnostic or therapeutic procedures beyond their usual care. This cross-sectional study will take place at 50 outpatient centers experienced in treating uncontrolled severe asthma, enrolling about 100 patients per region. The study will run from June 2024 to June 2027. During the single visit, researchers will collect information such as patients treatment regimens, use of oral corticosteroids, demographic details, clinical characteristics including comorbidities, lung function, and biomarkers like blood eosinophil counts and Immunoglobulin E levels. They will analyze these data to characterize treatment patterns and clinical outcomes in this population. No interventions are given, and patient safety is monitored through standard medical practice.